Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C.

Gynecol Oncol. 2019 Oct 15. pii: S0090-8258(19)31548-3. doi: 10.1016/j.ygyno.2019.09.024. [Epub ahead of print]

PMID:
31623857
2.

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.

Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M.

Clin Cancer Res. 2019 Oct 1. doi: 10.1158/1078-0432.CCR-19-0526. [Epub ahead of print]

PMID:
31573956
3.

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

Duska LR, Petroni GR, Lothamer H, Faust W Jr, Beumer JH, Christner SM, Mills AM, Fracasso PM, Parsons SJ.

Cancer Chemother Pharmacol. 2019 Mar;83(3):473-482. doi: 10.1007/s00280-018-3749-7. Epub 2018 Dec 8.

4.

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

Simonsen KL, Fracasso PM, Bernstein SH, Wind-Rotolo M, Gupta M, Comprelli A, Reilly TP, Cassidy J.

Eur J Cancer. 2018 Nov;103:259-266. doi: 10.1016/j.ejca.2018.07.127. Epub 2018 Oct 3.

5.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM.

Gynecol Oncol. 2018 Nov;151(2):202-207. doi: 10.1016/j.ygyno.2018.08.006. Epub 2018 Aug 31.

PMID:
30174176
6.
7.

A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.

Dillon PM, Petroni GR, Horton BJ, Moskaluk CA, Fracasso PM, Douvas MG, Varhegyi N, Zaja-Milatovic S, Thomas CY.

Clin Cancer Res. 2017 Aug 1;23(15):4138-4145. doi: 10.1158/1078-0432.CCR-16-2942. Epub 2017 Apr 4.

8.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

9.

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).

Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM.

Ann Oncol. 2017 Mar 1;28(3):505-511. doi: 10.1093/annonc/mdw635.

10.

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.

Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, Lankes HA, Manjarrez KL, Danet-Desnoyers GH, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G.

Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.

11.

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, Tenney ME, Rose PG, Fracasso PM.

Gynecol Oncol. 2016 Feb;140(2):204-9. doi: 10.1016/j.ygyno.2015.11.024. Epub 2015 Nov 23.

12.

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM.

Gynecol Oncol. 2015 Jul;138(1):36-40. doi: 10.1016/j.ygyno.2015.04.038. Epub 2015 May 6.

13.

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.

Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J.

Cancer Chemother Pharmacol. 2014 Aug;74(2):419-26. doi: 10.1007/s00280-014-2493-x. Epub 2014 Jun 11.

14.

Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.

Myint ZW, Sen JM, Watts NL, Druzgal TJ, Nathan BR, Ward MD, Boyer JE, Fracasso PM.

Clin Colorectal Cancer. 2014 Jun;13(2):127-30. doi: 10.1016/j.clcc.2013.12.003. Epub 2013 Dec 27. Review. No abstract available.

PMID:
24461491
15.

Coaching intervention as a strategy for minority recruitment to cancer clinical trials.

Fracasso PM, Goodner SA, Creekmore AN, Morgan HP, Foster DM, Hardmon AA, Engel SJ, Springer BC, Mathews KJ, Fisher EB, Walker MS.

J Oncol Pract. 2013 Nov;9(6):294-9. doi: 10.1200/JOP.2013.000982. Epub 2013 Oct 15.

16.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G.

J Clin Oncol. 2013 Nov 10;31(32):4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30.

17.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM.

Breast Cancer Res Treat. 2013 Jan;137(2):483-92. doi: 10.1007/s10549-012-2378-9. Epub 2012 Dec 15.

18.

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM.

Gynecol Oncol. 2012 Dec;127(3):456-61. doi: 10.1016/j.ygyno.2012.08.030. Epub 2012 Sep 7.

PMID:
22960004
19.

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Dec;127(3):506-10. doi: 10.1016/j.ygyno.2012.08.037. Epub 2012 Aug 31.

20.

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM.

Gynecol Oncol. 2012 Apr;125(1):158-62. doi: 10.1016/j.ygyno.2011.12.431. Epub 2011 Dec 22.

21.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Apr;125(1):54-8. doi: 10.1016/j.ygyno.2011.12.417. Epub 2011 Dec 11.

22.

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM.

Gynecol Oncol. 2011 Nov;123(2):182-6. doi: 10.1016/j.ygyno.2011.07.016. Epub 2011 Aug 5.

23.

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M, Fracasso PM.

Gynecol Oncol. 2011 Feb;120(2):224-8. doi: 10.1016/j.ygyno.2010.10.018.

24.

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37. doi: 10.1007/s00280-010-1410-1. Epub 2010 Aug 8.

25.

A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.

Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM.

Gynecol Oncol. 2010 Sep;118(3):303-7. doi: 10.1016/j.ygyno.2010.05.020. Epub 2010 Jun 14.

26.

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K.

Lancet Oncol. 2010 May;11(5):421-8. doi: 10.1016/S1470-2045(10)70054-1. Epub 2010 Mar 31.

27.
28.

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.

Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA.

Clin Cancer Res. 2009 Apr 1;15(7):2552-8. doi: 10.1158/1078-0432.CCR-08-1978. Epub 2009 Mar 24.

29.

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.

Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ.

J Nucl Med. 2008 Sep;49(9):1472-9. doi: 10.2967/jnumed.108.052316. Epub 2008 Aug 14.

30.

A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.

Read WL, Baggstrom MQ, Fracasso PM, Govindan R.

Chemotherapy. 2008;54(3):236-41. doi: 10.1159/000140468. Epub 2008 Jun 18.

PMID:
18560232
31.

Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.

Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL, McLeod HL.

Ann Oncol. 2008 Oct;19(10):1742-8. doi: 10.1093/annonc/mdn375. Epub 2008 Jun 4.

PMID:
18534963
32.

Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.

Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH.

J Clin Oncol. 2008 Jun 1;26(16):2674-82. doi: 10.1200/JCO.2007.14.9807.

PMID:
18509179
33.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE.

Cancer Chemother Pharmacol. 2009 Feb;63(3):451-8. doi: 10.1007/s00280-008-0756-0. Epub 2008 Apr 15.

PMID:
18414864
34.

A phase I study of docetaxel and bexarotene.

Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, Govindan R.

Chemotherapy. 2008;54(2):125-30. doi: 10.1159/000119706. Epub 2008 Mar 7.

PMID:
18332628
35.

A Phase I trial of weekly docetaxel and topotecan for solid tumors.

Lim WT, Baggstrom MQ, Read W, Fracasso PM, Govindan R.

Acta Oncol. 2008;47(2):311-5.

PMID:
17896192
36.

A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.

Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR.

Clin Cancer Res. 2007 Feb 1;13(3):986-93.

37.

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.

Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, Erlichman C, Okuno SH.

Cancer. 2006 Nov 15;107(10):2462-7.

38.

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

Fracasso PM, Blessing JA, Molpus KL, Adler LM, Sorosky JI, Rose PG.

Gynecol Oncol. 2006 Nov;103(2):523-6. Epub 2006 May 19.

PMID:
16712905
40.

A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.

Govindan R, Lim WT, Arquette MA, Goodner SA, Fears CL, Mortimer JE, Fracasso PM.

Oncol Rep. 2006 Jan;15(1):123-7.

PMID:
16328044
41.

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.

Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL.

Br J Cancer. 2005 Jul 11;93(1):46-53.

42.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.

Cancer. 2005 Jun 15;103(12):2584-9.

43.

Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.

Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, Kraut M, Ettinger DS, Dawkins F, Erlichman C.

J Clin Oncol. 2005 May 1;23(13):3069-73.

PMID:
15860865
44.

Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.

Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH.

Clin Cancer Res. 2004 Nov 1;10(21):7220-8.

45.

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.

Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V.

Leuk Res. 2003 Dec;27(12):1077-83.

PMID:
12921943
46.

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.

Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS.

J Clin Oncol. 2003 Aug 1;21(15):2856-9.

PMID:
12885801
47.

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.

Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA.

Cancer. 2003 Aug 1;98(3):610-7.

48.

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S.

Gynecol Oncol. 2003 Jul;90(1):177-80.

PMID:
12821360
49.

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.

Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL.

Ann Oncol. 2002 Nov;13(11):1819-25.

PMID:
12419757
50.

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.

Fracasso PM, Blum KA, Tan BR, Fears CL, Bartlett NL, Arquette MA, Clark RS.

Cancer. 2002 Nov 15;95(10):2223-9.

Supplemental Content

Loading ...
Support Center